During a live event, Nizar M. Tannir, MD and participants discussed how they think ahead to later lines of therapy when ...

Survival and Progression Metrics: Secondary and exploratory endpoints include duration of response, sustained MRD negativity, biochemical and clinical progression-free survival (PFS), time to a ...

Mitazalimab, in combination with standard chemotherapy, has exhibited continued promising efficacy and safety in treating ...

Michael Cole shares his decade-long battle with malignant pleural mesothelioma, highlighting treatment choices, resilience, and the vital doctor-patient relationship.

Combination therapy with relatlimab and nivolumab enhances treatment-free survival in advanced melanoma, offering promising ...

The study evaluated lifileucel in patients 18 years and older with unresectable or metastatic melanoma (stage IIIc or IV) who ...